📊 NKTX Key Takeaways
Is NKTX a Good Investment? Thesis Analysis
Nkarta is a pre-revenue biotech company with unsustainable cash burn dynamics. At an annual burn rate of $89.9M against only $39.6M in cash, the company faces critical funding pressure within 5-6 months. While the balance sheet shows no debt and reasonable liquidity, the absence of revenue combined with $122M in annual operating losses indicates the company has not yet achieved commercial viability.
Why Buy NKTX? Key Strengths
- No long-term debt burden (debt/equity ratio of 0.00)
- Strong liquidity position with 12.69x current ratio relative to liabilities
- Reasonable asset base of $404.2M with positive stockholders equity of $312.3M
NKTX Investment Risks to Consider
- Pre-revenue stage with zero commercial product revenue and no clear path to near-term commercialization
- Critical cash runway: $39.6M in cash against $89.9M annual free cash flow burn means less than 6 months of liquidity at current burn rate
- Massive operating losses of $122M annually indicate unsustainable R&D and operational spending relative to resources
- Company will require dilutive equity financing or dramatic operational restructuring to avoid cash depletion
- Minimal insider confidence with only 2 Form 4 filings in 90 days suggests low management activity
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway projections
- Announcement of financing events and dilution impact on shareholders
- Clinical trial progression milestones and FDA approval timelines
NKTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 12.69x current ratio provides a solid financial cushion.
NKTX Profitability Ratios
NKTX vs Healthcare Sector
How Nkarta, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NKTX Overvalued or Undervalued?
Based on fundamental analysis, Nkarta, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NKTX Balance Sheet & Liquidity
NKTX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Nkarta, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.60 indicates the company is currently unprofitable.
NKTX Growth Metrics (YoY)
NKTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $115.0K | -$2.7M | N/A |
| Q2 2020 | $2.3K | -$3.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NKTX Capital Allocation
NKTX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Nkarta, Inc. (CIK: 0001787400)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NKTX
What is the AI rating for NKTX?
Nkarta, Inc. (NKTX) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NKTX's key strengths?
Claude: No long-term debt burden (debt/equity ratio of 0.00). Strong liquidity position with 12.69x current ratio relative to liabilities.
What are the risks of investing in NKTX?
Claude: Pre-revenue stage with zero commercial product revenue and no clear path to near-term commercialization. Critical cash runway: $39.6M in cash against $89.9M annual free cash flow burn means less than 6 months of liquidity at current burn rate.
What is NKTX's revenue and growth?
Nkarta, Inc. reported revenue of $0.0.
Does NKTX pay dividends?
Nkarta, Inc. does not currently pay dividends.
Where can I find NKTX SEC filings?
Official SEC filings for Nkarta, Inc. (CIK: 0001787400) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NKTX's EPS?
Nkarta, Inc. has a diluted EPS of $-1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NKTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nkarta, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NKTX stock overvalued or undervalued?
Valuation metrics for NKTX: ROE of -33.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NKTX stock in 2026?
Our dual AI analysis gives Nkarta, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NKTX's free cash flow?
Nkarta, Inc.'s operating cash flow is $-88.7M, with capital expenditures of $1.2M.
How does NKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -33.3% (avg: 15%), current ratio 12.69 (avg: 2).